Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Neoplasms
Interventions: Niraparib, Pembrolizumab, TSR-042 (Dostarlimab); Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more

Conditions: Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Interventions: Neihulizumab Treatment, Conventional Treatment; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Rheumatoid Arthritis
Interventions: no intervention; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 34
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more

Conditions: Liver Cancer
Interventions: Dynamic Contrast Enhanced Computed Tomography; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Presbyopia
Interventions: LD118033 contact lens, PureVision multifocal contact lens; Device
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Inflammation
Interventions: Pioglitazone 15mg, pioglitazone 30mg, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 20 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2003
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: Dato-DXd; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more

Conditions: Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Interventions: Ruxolitinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Acne Vulgaris
Interventions: CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more

Conditions: Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: amphotericin B deoxycholate, nystatin; Drug
Lead sponsor: Aronex Pharmaceuticals; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 59
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: AQ4N (Chemotherapy); Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: CodaLytic; Biological
Lead sponsor: Codagenix, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Canton, Ohio

Conditions: Type 2 Diabetes
Interventions: Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chula Vista, California • Orlando, Florida

Conditions: Anemia
Interventions: Venofer; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Palmar Hyperhidrosis
Interventions: Dexmecamylamine HCl, Placebo; Drug · Other
Lead sponsor: Atacama Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: San Diego, California • St Louis, Missouri • Norfolk, Virginia

Conditions: Smoking, Alcohol Abuse, Drug Abuse
Interventions: Self-administered computerized assessment for tobacco, substance abuse, and alcohol use., Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 758 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Contraception, Ovulation
Interventions: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Angioedema
Interventions: Placebo, Lanadelumab; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more

Conditions: Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions: Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging; Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice, Risk Reduction Behavior
Interventions: Educational Intervention, Nudge; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 99 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Laparoscopic Appendectomy
Interventions: Bupivacaine, Placebos; Drug
Lead sponsor: Metro Health, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: Inflammatory Breast Carcinoma
Interventions: 89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: PB127 for Injectable Suspension; Drug
Lead sponsor: Point Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Tucson, Arizona • Burlingame, California • Long Beach, California + 33 more

Search by objective public record fields.

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

Dynamic Contrast Enhanced Computed Tomography to Assess Radiation Therapy in Liver Cancer Patients

A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contact Lens

Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Dynamic Assessment and Referral System - Evaluation

Ovulation Incidence in Oral Contraceptive Users

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents

A Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease